Applied DNA Sciences APDN shares are trading higher after the company published a press release highlighting the FDA's findings on sensitivities in specific COVID-19 tests. The company says its' Linea COVID-19 Assay Kit is '1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7).'
Applied DNA Sciences is a provider of DNA-based supply chain, anti-counterfeiting, and anti-theft technology. The company provides its products and services under the brand of SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon.
Applied DNA Sciences shares were trading up 80% to $10.33 at publication time. The stock has a 52-week high of $16.39 and a 52-week low of $2.52.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.